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Gerard F Curley1,2 and Arthur S Slutsky3,4*Abstract
This review documents important progress made
in 2013 in the field of critical care respirology, in
particular with regard to acute respiratory failure and
acute respiratory distress syndrome. Twenty-five
original articles published in the respirology and
critical care sections of Critical Care are discussed in
the following categories: pre-clinical studies, protective
lung ventilation – how low can we go, non-invasive
ventilation for respiratory failure, diagnosis and prognosis
in acute respiratory distress syndrome and respiratory
failure, and promising interventions for acute respiratory
distress syndrome.evaluated the effects of high-stretch mechanical ventila-Introduction
Acute respiratory distress syndrome (ARDS) represents a
recognizable common pattern of acute alveolar-capillary
injury in critically ill patients. Despite numerous random-
ized clinical trials aimed at regulating the lung inflamma-
tory response during ARDS [1], the only proven therapies
to consistently reduce mortality are a protective ventila-
tion strategy and prone positioning [2,3]. This review out-
lines the progress made in basic science and clinical
respiratory critical care research in 2013, which is likely to
further our understanding of pathophysiology in ARDS
and acute respiratory failure and potentially identify new
therapeutic strategies. This includes pre-clinical investiga-
tion, observational studies and meta-analysis, and phase II
and III trials.
Pre-clinical studies
Although we have made great strides in understanding
the pathogenesis of respiratory failure in ARDS, we do
not yet have sufficient understanding of the underlying
mechanisms of alveolar-capillary barrier dysfunction in* Correspondence: slutskya@smh.ca
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commonly used; unfortunately, many are poor models
for the majority of human diseases [6]. Crucial genetic,
molecular, immunologic, and cellular differences between
humans and mice prevent animal models from serving as
effective and reliable surrogates of human ARDS [7]. The
failure to translate from animals to humans is likely due in
part to poor methodology as well as the failure of the
models to accurately mimic the human disease condition
[8,9]. It has been recommended that experiments be de-
signed in both genders and in different age groups of
animals and that all data, both positive and negative, be
published [10].
In this respect, a study by Setzer and colleagues [11]
tion on ‘old’ and ‘young’ rats. The conclusion drawn from
these experiments was that older rats are more susceptible
to injury induced by high tidal volumes, including enhan-
ced leukocyte migration and alveolar-capillary barrier dys-
function. Animal age has been regarded as a confounding
factor in pre-clinical experiments in ARDS, given that the
evidence for a potential therapeutic is usually derived from
experiments in young animals, which are not represen-
tative of adult disease. Age is indeed associated with com-
promised physiologic and immunologic function, even in
the absence of disease [12]. Age-dependent changes in re-
spiratory and cardiovascular reserve are well documented
[13,14]. The age-dependent deterioration of the immune
system results in increased susceptibility to viral and bac-
terial infections, opportunistic infections, reactivation of
latent viruses, decreased responses to vaccination, auto-
immune diseases, and neoplasias in humans and animals
[15]. In addition, there is an age-dependent systemic
inflammatory state in humans and animals even in the
absence of disease [16]. The lungs of aged individuals also
exhibit an elevated basal inflammatory state [17], which is
primed to respond in an overexuberant manner following
an infection or injury. Regardless of whether local (organ-
specific) or systemic, the elevated inflammatory state is
characterized by elevated basal levels of the proinflam-
matory mediators IL-6, IL-8, IL-1, and tumor necrosis
factor-alpha [18].entral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
is time, the article is available under the terms of the Creative Commons Attribution
y/4.0), which permits unrestricted use, distribution, and reproduction in
erly credited. The Creative Commons Public Domain Dedication waiver
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less susceptible to ventilator-induced lung injury (VILI)
than older rats. Failure to adequately consider variables
such as age, as well as comorbidity, physiological status,
and timing of drug administration, contributes to the dis-
parity between the results of animal models and clinical
trials.
Kim and colleagues [19], in an effort to mimic and
modify the lung injury that occurs during neutropenia
recovery, administered tyrosine kinase inhibitors to mice
that had been rendered neutropenic. Indeed, this elegant
and physiologically relevant study also identified a separ-
ate potential therapeutic target, platelet-derived growth
factor (PDGF) receptor β. PDGF has been implicated as
a pro-fibrotic stimulus in ARDS [20]. However, the α
and β receptors for PDGF mediate different functions:
the β receptor is important in mediating pro-fibrotic cell
migration, whereas the α receptor inhibits migration.
Studies such as these, which identify novel molecular
targets in clinically relevant animal models, portend a
brighter future for pharmacologic intervention in ARDS.
In another important pre-clinical study, Protti and
colleagues [21] evaluated the injurious effects of high
positive end-expiratory pressure (PEEP) in healthy lungs
during low tidal volume mechanical ventilation. PEEP
has become a central component of protective lung
ventilation strategies. Although the degree of alveolar
over-distention to which animals are subject is central to
the pathogenesis of VILI, it also appears likely that un-
stable lung units in ARDS may be damaged by repeated
opening and closing during tidal ventilation [22]. PEEP
may prevent diffuse alveolar damage in experimental
models during prolonged ventilation at high lung volumes
by stabilizing distal lung units [23]. The flip-side of overin-
flation and overdistension, the potential for low-volume
injury, has been addressed by experiments in isolated rat
lungs [24] that demonstrated that repetitive opening and
collapse can lead to a decrease in lung compliance and
injury to the epithelial cells that line small airways and
alveolar ducts. Protti and colleagues have addressed the
potential of high PEEP to increase alveolar capillary per-
meability and exacerbate pulmonary edema. Previous
studies have shown that only major increases in static lung
volume alter epithelial permeability to large molecules
during static inflation [25,26]. In contrast, prolonged cyc-
lic lung inflation during mechanical ventilation produces
major alterations in epithelial permeability to proteins,
both large and small [27]. The study by Protti and col-
leagues confirms that high PEEP does not increase pul-
monary edema in healthy lungs, even after subsequent
removal of the PEEP [21].
Finally, Vecchi and colleagues [28] used an ovine oleic
acid injury model to determine the effects of lowering
radiation dose on the quality of computed tomography(CT) images. This study demonstrated that a reduction
of effective radiation dose of up to 70% can be achieved
with minimal effects on lung quantitative results and
that low-dose CT could therefore be a valuable tool for
the characterization of lung compartment distribution
and possibly for monitoring the progression of ARDS,
with a lower risk of exposure to ionizing radiation.
This study has formed the basis for an observational
study that reached similar conclusions in patients with
ARDS [29].
Protective lung ventilation – how low should we go
The possibility that mechanical ventilation can actually
worsen lung injury is now accepted as reality [30]. More
recent attempts to adjust ventilation strategies to further
reduce harm have met with limited success [31-33]. Even
with contemporary low-stretch strategies, it appears dif-
ficult to avoid regional areas of high lung stretch [34] in
some patients. Quantitative assessment of CT images in
humans with severe ARDS indicates that the amount of
normally aerated tissue - the so-called ‘baby lung’ - is
variable and may be as low as 200 mL [35]. A 6 mL/kg
tidal volume applied to these ‘baby lungs’ results in air-
way pressures in the range of 30 to 35 cm H2O (which
in many patients is likely to be injurious) [36]. In this
regard, the mean peak airway pressure in the treatment
arm of the ARDS net low tidal volume study was 34 cm
H2O [36]. Other diseased lung regions may be subject to
even greater distention and greater regional intra-alveolar
and airway pressures [37]. However, further lowering the
tidal volume to prevent lung injury may worsen atelectasis
[38], which can also cause harm [39].
In this respect, a 2013 pilot randomized crossover
study [40], which compared a 4 mL/kg tidal volume
mechanical ventilation strategy with 6 mL/kg in patients
with ARDS, is promising. Patients who were ventilated
with a tidal volume of 4 mL/kg had decreased cyclic
recruitment-derecruitment and end-inspiratory hyperin-
flation on dynamic CT, as well as lower plateau airway
pressures, compared with those ventilated with 6 mL/kg.
This study is intriguing not only for the potential en-
hanced lung protection evident on radiologic imaging
but also for the questions it poses for the management
of the resultant hypercapnia. Hypercapnia is common in
ARDS. Managing elevated arterial partial pressure of
carbon dioxide (PaCO2) by increasing tidal volume is now
known to be unacceptable in many situations; however,
management by increasing the respiratory rate, as in this
study, is common but of uncertain impact. For example,
increasing respiratory frequency from 12 to 30 breaths per
minute adds over 25,000 additional opening and closing
cycles per day to an already injured lung, and laboratory
data suggest that this approach can be associated with
additional lung injury [41].
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the need for increased respiratory rate or increased tidal
volume, but this therapy remains unproven. Adding to
the uncertainty around lowering tidal volumes further is
the fact that hypercapnia might contribute direct benefit
in patients with ARDS [42]. A multivariate analysis of
the ARDS Network low tidal volume study [2], after
controlling for other variables predictive of mortality,
found that the patients who had moderate hypercapnic
acidosis (HCA) (pH 7.15 to 7.35, PaCO2 45 to 65 mm Hg)
on study day 1 had a significantly lower odds ratio of
death at 28 days, but only in the 12 mL/kg tidal volume
group, a result consistent with a protective effect of HCA
in VILI [43]. Though not proof of cause and effect, these
data support the concept that hypercapnia during low
tidal volume ventilation might contribute direct benefit in
patients with ARDS.
Another randomized crossover study in 2013 addressed
this very point. Natalini and colleagues [44] ventilated
16 patients with ARDS for 30 minutes with either low
(6 mL/kg) or high (12 mL/kg) tidal volume ventilation and
then obtained hemodynamic measurements, including
cardiac index and oxygen delivery. Cardiac index and oxy-
gen delivery index were increased with low compared with
high tidal volume ventilation, whereas oxygen extraction
ratio decreased. The enhanced cardiac index was posi-
tively associated with PaCO2 variation and not with alter-
ations in tidal volume or airway pressure.
The potential for harm with hypercapnic or metabolic
acidosis is clear, whether due to acute exposure (for ex-
ample, raised intracranial pressure, pulmonary hyper-
tension) or exposure for prolonged periods of time (for
example, increased risk of infection) or at high concen-
trations. Although HCA has a direct negative inotropic ef-
fect, the indirect hypercapnia-mediated sympatho-adrenal
effects of increased heart rate and decreased afterload lead
to a net increase in cardiac output [45]. It is somewhat
reassuring to note that HCA can increase tissue oxygen
delivery in moderate to severe ARDS, as in this study [44].
Finally, a systematic review in 2013 [46] evaluated the
effect of low tidal volumes at initiation of mechanical
ventilation on the risk of developing ARDS. Twelve
observational studies and one randomized controlled
trial (RCT) were included in the analysis. In the only
RCT included [47], use of larger tidal volumes was more
likely to lead to development of ARDS. Additionally, the
majority of the observational data demonstrated increased
ARDS incidence with larger tidal volumes. However, as
pointed out by the authors, there was a great deal of
heterogeneity in the studies, precluding a formal meta-
analysis. Adding to the uncertainty in this area is the
use of ideal body weight and predicted body weight
interchangeably, while predicted body weight has been
used to guide tidal volume adjustment in most studies.This study and others highlight the fact that the ideal ap-
proach to ventilate patients without ARDS is unknown.
Two recent multicenter RCTs were not included in
this systematic review. The first study concluded that
the use of low tidal volumes for ventilation during surgery
improves postoperative outcomes [48]. However, this study
used low tidal volume, PEEP and recruitment maneu-
vers, versus conventional tidal volumes without PEEP,
in patients who were deemed high risk for developing
pulmonary complications [48]. In contrast, the most
recent study - PROVHILO (Protective Ventilation using
High versus Low positive end-expiratory pressure) trial
[49] - concluded that high PEEP and recruitment maneu-
vers did not protect against postoperative pulmonary com-
plications but led to an increased incidence of hypotension
intraoperatively.
Non-invasive ventilation and respiratory failure
Non-invasive ventilation (NIV) can reduce intubation
and mortality rates in patients with severe acute exacer-
bation of chronic obstructive pulmonary disease [50] or
cardiogenic pulmonary edema [51]. The role of NIV in
patients with ARDS is controversial, not least because
lung-protective ventilation, a strategy with an 8.8% abso-
lute reduction in the risk of death, is difficult to apply in
this setting [2]. Previous studies have shown that NIV
applied in patients with ARDS avoids intubation in 54%
of the treated patients, with best efficacy in mild ARDS
[52]. However, this result could be related to the experi-
ence of the center where it is implemented. Antonelli
and colleagues [52] also reported that a Simplified Acute
Physiology Score II of more than 34 calculated 24 hours
after the admission to the ICU and arterial partial pres-
sure of oxygen/fraction of inspired oxygen (PaO2/FiO2)
of not more than 175 after the first hour of NIV are in-
dependently associated with the need for endotracheal
intubation, and the ICU mortality rate is significantly
higher in those who require intubation.
Two recent studies addressed the question of the risks
and benefits of NIV in a more mixed population of ICU
patients: one was an observational cohort study that
looked at intubation rates and outcome in patients present-
ing to ICU with hypoxemic respiratory failure [53], and the
other was an RCT of NIV after weaning of mechanical
ventilation and extubation in patients initially presenting
with hypoxemic respiratory failure [54].
Thille and colleagues [53] prospectively studied 113 pa-
tients receiving NIV for respiratory failure, 82 of whom
had ARDS and 31 who had respiratory failure from other
causes. Intubation rates were significantly higher in pa-
tients with ARDS (61% versus 35%), and NIV failure was
highest among those having a PaO2/FiO2 of less than
150 mm Hg. Importantly, ICU mortality rate did not differ
according to the time to intubation. Previous studies have
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tory failure is independently associated with poor outcome
as compared with patients intubated without prior
NIV [55]. As such, the study by Thille and colleagues
is reassuring. In this study, as in that of Antonelli and
colleagues [52], there was a low risk of NIV failure in pa-
tients with mild ARDS, and almost all patients with severe
ARDS required intubation. The grey area appears to be
moderate ARDS, where Thille and colleagues [53] and
Antonelli and colleagues [52] agree that a PaO2/FiO2 ratio
cutoff of 150 mm Hg (20 kPa) appeared to more accur-
ately segregate patients who failed from those who were
successfully treated with NIV.
Ornico and colleagues [54], in an RCT, studied the use
of NIV versus oxygen mask immediately after extubation
in a mixed population of patients with respiratory failure.
The use of NIV post-ICU extubation also remains a
contentious area, with earlier ‘prophylactic’ use seemingly
preferential to treatment of established respiratory failure
in this group of patients. There is, however, no consensus
regarding the optimal time period to provide NIV after
extubation, and the findings of meta-analyses [56] reflect
and reinforce the uncertainty over the use of NIV in this
area. The findings of Ornico and colleagues support the
suggested benefit of NIV in a mixed respiratory failure
population immediately after extubation. The use of NIV
in treating established respiratory failure after extubation
may not be effective and could be harmful [57].
Finally, a study by Oto and colleagues [58] compared
the application of continuous positive airway pressure
(CPAP) and ventilation via a nasal mask with that of a
full face mask, during unconsciousness induced by general
anesthesia. Nasal CPAP was more effective in maintaining
upper airway patency in unconscious subjects and pro-
duced more effective tidal volume. This study has implica-
tions for the practice of emergency mask ventilation in the
unconscious subject, which is carried out almost exclu-
sively by full face mask ventilation. Nonetheless, it must
be emphasized that the efficacy of any CPAP mask - nasal
or full face - depends on head and jaw position during
unconsciousness.
Diagnosis and prognosis in acute respiratory
distress syndrome and respiratory failure
Patient heterogeneity - that is, the fact that patients with
ARDS have a wide spectrum of disease severity as well
as markedly different underlying pathophysiology (for
example, sepsis versus trauma) - has been, and continues
to be, a hallmark of ARDS and respiratory failure popula-
tions within clinical trials. This problem remains a major
impediment to defining a responsive patient population for
a specific intervention, and this issue remains a major un-
met medical need in ARDS clinical trial design. Since the
diagnosis of ARDS is based on a combination of clinical,oxygenation, hemodynamic, and radiographic criteria,
most studies include a highly heterogeneous group of
patients. Even severe hypoxemia, the cardinal feature of
ARDS, does not reliably delineate disease severity or
predict the development and progression of the syn-
drome or response to treatment in any given patient.
The PaO2/FiO2 ratio is the hallmark for assessing hyp-
oxemia in patients with ARDS. However, current ARDS
definitions do not mandate a standardized procedure
for its measurement despite our awareness that changes
in PEEP and FiO2 alter the PaO2/FiO2 [59,60]. This con-
cern is highlighted in two recent observational reports
in which the PaO2/FiO2 at ARDS onset was incapable of
separating patients into distinct categories of severity
associated with significantly different mortalities [61,62].
However, a persistently low PaO2/FiO2 is associated with
a poor outcome and may be a marker of failure to respond
to conventional therapy [5,6]. This limitation (that is, our
inability to define a more homogeneous group of ARDS
patients with similar disease severity) may explain why in
the last 14 years since the publication of the ARDSnet
trial, only two RCTs have had positive results [3,63].
In both trials, only patients with a PaO2/FiO2 thresh-
old under a specific level (150 mm Hg, 20 kPa) that
persisted 18 to 36 hours were enrolled. Thus, a standard-
ized method for assessing lung injury severity must be
mandatory to identify a homogeneous group of patients
with ARDS.
Biomarkers
A number of strategies have been proposed to deal with
the heterogeneity problem in ARDS trials. One approach is
the use of biomarkers to define more homogenous subsets.
Biomarkers linked to the mechanism of action of the
treatment would be ideal to either identify the subset or
monitor response to therapy. Although various putative
biomarkers have been investigated in the context of ARDS,
their correlation with disease development and disease
outcome has been inconsistent. In this respect, two studies
deserve consideration. De Luca and colleagues [64] and de
Kretser and colleagues [65] evaluated potentially important
biomarkers in infant ARDS and in a mixed population of
patients with acute respiratory failure, respectively. De
Luca and colleagues [64] evaluated the role of elevated
levels and activity of secretory phospholipase A2 (sPLA2)
in bronchoalveolar lavage (BAL) fluid in infants with ARDS
as well as the consequences of its elevation, including
increased free fatty acid levels and reduced quantity and
quality of surfactant proteins. sPLA2 activity was correlated
with surface tension, compliance and oxygenation, as well
as clinical outcomes, including pediatric ICU stay, duration
of mechanical ventilation, and oxygen therapy. This study
identifies sPLA2 as both a potential target and a marker of
disease severity in this population.
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addresses one of the challenges of biomarker research:
the difficulty of validating a diagnostic biomarker of
ARDS or any other cause of respiratory failure. The ideal
marker is one that can predict the development of
disease in ‘at-risk’ patients and also distinguish patients
with true non-cardiogenic pulmonary edema from those
with congestive heart failure, bilateral pneumonia, lym-
phangitic carcinomatosis, and all other causes of bilateral
lung infiltrates and hypoxemia. Thus, at a minimum, a
biomarker identified in medical-surgical ICU patients ‘at
risk’ of ARDS needs to be validated in ‘at-risk’ trauma
patients and also in patients with non-ARDS causes of
respiratory failure. The data of De Kretser and colleagues
indicate that the activins A and B, members of the trans-
forming growth factor-beta superfamily, are not useful
in distinguishing different subtypes of respiratory failure.
However, elevated levels of these proteins are linked to
poor outcomes, including risk of death.
Aids for diagnosis in respiratory failure
Two studies focused on methods for enhancing diagnostic
sensitivity in respiratory failure. Using a retrospective de-
sign, Yoo and colleagues [66] identified the causes of dif-
fuse pulmonary infiltrates in 214 cancer patients admitted
to the ICU for respiratory failure. Invasive diagnostic tests
such as BAL and transbronchial and surgical lung biopsy
increased diagnostic accuracy and altered clinical care.
BAL exclusively provided etiologic diagnoses in one third
of patients; lung biopsy simultaneously performed with
BAL increased diagnostic yield. This is in contrast to pre-
vious studies that demonstrated that the additional diag-
nostic yield of BAL in combination with non-invasive tests
is relatively low [67]. The study by Yoo and colleagues [66]
reaffirms the importance of bronchoscopy and biopsy for
the diagnosis of diffuse pulmonary infiltrates, at least in the
immunocompromised patient subgroup.
The relative ease of bedside ultrasound (US) examin-
ation and the availability of user-friendly, inexpensive,
portable equipment have made chest ultrasonography an
interesting alternative method for diagnosis of respiratory
disease. In some studies, chest ultrasonography has been
shown to be more sensitive in detecting pneumothorax
than chest x-ray performed on a supine patient [68]. The
marked increase in use of bedside US in recent years has
led to the publication of a number of trials evaluating this
technology against chest radiography. Alrajab and collea-
gues [69] conducted a meta-analysis of the available litera-
ture that included high-quality articles, avoiding studies
that evaluated populations with known pneumothorax
and studies that used verification methods other than
chest radiography or CT. The pooled sensitivity of US in
this study was lower than in previous analyses (78.6% ver-
sus 88%) but remained superior to that of chest radiographyor CT, thus confirming the accuracy of US for the diagno-
sis of pneumothorax, particularly in the setting of trauma.
Assessment of disease severity in respiratory failure
Although a significant number of patients with respiratory
failure die or require prolonged mechanical ventilation, the
tools for predicting mortality and morbidity in this group
of patients are limited [70]. As a high-cost technology (that
is, nursing and medical care), mechanical ventilation is
increasingly scrutinized because of the increased focus
on improving cost efficiency and documenting patient
outcomes. Unfortunately, our current ability to accurately
assess practices and patient outcomes from assisted venti-
lation is hindered by wide variations in standard practices
and considerable disagreement among physicians regard-
ing many aspect of ventilatory management. Altered lung
mechanics and abnormal gas exchange are hallmarks of
impaired lung function in ARDS and are of prognostic
significance [71], although assessment of lung mechanics
does not form part of the Berlin definition of ARDS. The
presence of persistent shock, renal failure, increased age,
immunosuppression, underlying cause of lung injury, and
overall severity of illness were previously identified as im-
portant non-pulmonary outcome determinants [72]. How-
ever, poor discrimination by current prediction models in
observational cohorts suggests that unmeasured factors
may account for failure to wean and increased mortality
in ventilated patients [73].
A number of studies in 2013 attempted to improve
our prediction of severity of disease, duration of mech-
anical ventilation, and mortality from respiratory failure.
Supinski and Callahan [74] studied the effects and etiology
of diaphragm weakness in mechanically ventilated patients
on outcome, including mortality and need for long-term
ventilation. The authors used an objective measure of
diaphragm strength, bilateral anterior magnetic phrenic
nerve stimulation using esophageal and gastric pressure
sensors, to capture maximal transdiaphragmatic pressure
with bilateral stimulation of the phrenic nerves. They found
that mortality was 49% in the patients with the weakest
diaphragms but was only 7% for patients with mild dia-
phragm weakness. In addition, patients with the weakest
diaphragms took longest to wean from mechanical venti-
lation, which was a better predictor of failure to wean than
other indices of lung dysfunction. Finally, in this study,
evidence of infection was a predictor of strikingly lower
levels of diaphragm strength than that observed for non-
infected patients [74].
Several authors who have studied diaphragm strength
invasively have reported that patients with greater dia-
phragm strength are more likely to successfully wean than
patients with weaker diaphragms [75,76]. Animal and lim-
ited human studies have found that anti-oxidants and
physical activity can block or attenuate ventilator-induced
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tion use [77], but more work investigating cellular and
functional changes in the human diaphragm following
mechanical ventilation is needed.
A separate study described a simple bedside index, the
ventilatory ratio (VR), which uses minute ventilation and
PaCO2 to calculate an index of ventilatory efficiency [78].
VR was an independent predictor of mortality in a general
ICU population and was associated with worse outcome
after adjusting for Acute Physiology and Chronic Health
Evaluation II score. The advantage of VR is that it is a
quick bedside index that identifies patients with severe
disease, and the study shows that it is clinically useful in
mechanically ventilated patients. Further confirmatory
studies are required, however, in a cohort of patients with
respiratory failure only.
In another study designed to assess severity of disease
during mechanical ventilation, Al-Rawas and colleagues
[79] attempted to use the expiratory time constant to
provide a real-time measure of inspiratory plateau pres-
sure (Pplat) and respiratory system compliance. Pplat is
a surrogate of respiratory system compliance (when
PEEP and tidal volume are specified), and monitoring
Pplat may be helpful during lung-protective mechanical
ventilation. However, it is difficult to measure in patients
who are breathing spontaneously or who are on pressure
support. Al-Rawas and colleagues [79] found that the
expiratory time constant method was an excellent pre-
dictor of plateau pressure, compliance, and resistance
for acute respiratory failure patients receiving various
modes of ventilatory support.
Carlucci and colleagues [80] studied the relationship
between patient ventilator asynchrony, a factor known
to predict poor outcome in ICU ventilated patients
and poor tolerance of NIV, and respiratory mechanics
in patients enrolled in a home ventilator program.
The occurrence of asynchrony was not correlated to
respiratory mechanics recorded during spontaneous
breathing and did not differ between patients with
obstructive or restrictive disease. As the incidence of asyn-
chrony was high at 30%, other factors, such as ventilator
settings, may explain patient ventilator asynchrony in this
population.
Kushimoto and colleagues [81] evaluated the relation-
ship between ARDS severity (as determined by the
Berlin definition) and extra-vascular lung water (EVLW)
and pulmonary vascular permeability, as assessed by the
transpulmonary single thermodilution method. ARDS
progression outlined by the Berlin definition was associ-
ated with increases in EVLW content and pulmonary
microvascular permeability. The Berlin definition also
distinguished the severity categories of ARDS with good
predictive validity for mortality, the severity of physio-
logical derangements, and organ failure [81].Finally, two studies outlined the factors associated with
poor outcome during rescue therapy for ARDS. Camporota
and colleagues [82] studied physiological predictors
of survival in patients who required high-frequency
oscillatory ventilation (HFOV), whereas Aubron and
colleagues [83] determined the factors associated with
outcome in patients on extra-corporeal membrane oxy-
genation (ECMO) support. The study by Camporota and
colleagues came before publication of the OSCILLATE
(Oscillation for Acute Respiratory Distress Syndrome
Treated Early) [84] and OSCAR (Oscillation in ARDS)
[85] trials, two large multicenter trials of HFOV in ARDS
that showed no difference in survival between patients
ventilated with HFOV or conventional mechanical ventila-
tion, and in fact, in OSCILLATE, showed an increased risk
of death in the HFOV group. The study by Camporota
and colleagues is interesting as an early improvement in
PaO2/FiO2 ratio was a predictor of survival at 30 days;
patients in this cohort did not survive if there was no
improvement in gas exchange within 3 hours [82]. The
evidence from the two large trials of HFOV has led to a
re-evaluation of the use of this therapy in patients with
ARDS. A more individualized approach, using the know-
ledge gained from studies such as the one by Camporota
and colleagues, which identifies responders to HFOV
combined with the assessments of cardiac function such
as echocardiography, could be incorporated into fu-
ture HFOV protocols to try to increase the safety of
adult HFOV.
The surprising failure of HFOV to show an outcome
benefit in ARDS in these studies has led to increased
focus on extra-corporeal technologies as rescue therapy
for severe ARDS. The study by Aubron and colleagues
[83] identified bleeding as the single most frequent and
most important complication in patients undergoing
ECMO, whereas the volume of blood transfused on
veno-arterial ECMO, or the platelet volume requirement
on veno-venous ECMO, was an independent risk factor
for death. Further studies may indicate whether manage-
ment of bleeding and coagulopathy can impact on out-
come in this severely ill cohort of patients.
Promising interventions for acute respiratory
distress syndrome
Despite 159 RCTs and 29 meta-analyses on ARDS treat-
ment, only three specific interventions have been found
to decrease ARDS mortality [1]. The available evidence
seems to support a reduction in overall mortality with
low tidal volume ventilation and also with prone posi-
tioning and neuromuscular blockade among patients
with severe ARDS. These three interventions may be the
only ones that can be currently recommended for routine
clinical use. It must be noted that the survival benefit of
these specific interventions has been demonstrated in only
Note: This article is part of a collection of Year in review articles
in Critical Care. Other articles in this series can be found at
http://ccforum.com/series/Yearinreview2013
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further validation or confirmatory trial. In 2013, investiga-
tors evaluated these and other interventions in systematic
reviews, pilot studies, and RCTs in an effort to consolidate
the supportive evidence and to identify new interventions
for this devastating syndrome.
A post hoc analysis [86] of the ARDS Network low
tidal volume study [2] found that the lower the plateau
pressure, the better the patient’s chances of survival. These
and other data [34] have prompted the use of even lower
tidal volumes in an effort to provide additional benefit in
ARDS, with the use of extra-corporeal, pumpless arterio-
venous approaches to CO2 removal [87]. Forster and col-
leagues [88] studied the effects of low-flow CO2 removal
integrated into a renal-replacement circuit in 10 patients
who had ARDS and acute kidney injury and who under-
went renal replacement therapy. This low-flow hollow-
fiber gas exchanger implemented in a renal-replacement
circuit led to a rapid, partial, or complete correction of the
pH and a significant reduction of the partial pressure of
CO2 within 4 hours. A marked reduction of vasopressor
needs and an improved hemodynamic stability occurred
in five of six unstable patients. This small proof-of-
concept study must be followed by larger controlled stud-
ies in order to assess the impact of low-flow CO2 removal
on ventilator management and patient prognosis.
In marked contrast to this study, Spieth and colleagues
[89] tested the efficacy of ‘noisy’ pressure support venti-
lation in a randomized crossover study of 13 mechanic-
ally ventilated patients with respiratory failure. Noisy
pressure support ventilation delivers a random variation
of pressure support to the patient in an attempt to
mimic normal tidal ventilation. All of the patients in this
study were already on assisted spontaneous breathing
prior to the start of the study. This mode of ventilation
was found to be safe and to result in similar gas exchange
and hemodynamics when compared with conventional
pressure support and was associated with improved
patient-ventilator synchrony compared with conventional
pressure support ventilation. Improved synchrony has
been well documented during assisted mechanical ventila-
tion modes that apply pressure support proportionally to
the inspiratory effort, like Proportional Assist Ventilation
and Neurally Adjusted Ventilator Assist [90,91]. The im-
portance of these modes in improving clinically important
outcomes remains to be tested.
Finally, two systematic reviews evaluated emerging sup-
portive treatments for ARDS - neuromuscular blockers
[92] and ECMO [93] - both treatments that have not yet
been incorporated into standard ARDS management
worldwide. Alhazzani and colleagues [92] analyzed the
combined effects of RCTs that administered a 48-hour
infusion of cisatracurium besylate to patients with ARDS
on mortality, ICU and hospital stay, duration of mechanicalventilation, and ICU-acquired weakness. Analysis from
three pooled trials involving 431 patients demonstrated
improvement in mortality without an increase in the risk
of ICU-acquired weakness. As these trials were derived
from a single group of investigators at multiple centers
across France, further international multicenter trials are
warranted to confirm the generalizability of these findings.
Zangrillo and colleagues’ [93] meta-analysis of ECMO
for H1N1-induced ARDS included observational studies
only. They analyzed 266 patients from eight studies and
suggested an overall in-hospital mortality of 27.5%, a
median ICU stay of 25 days, and an overall median total
length of stay of 37 days. However, the highly variable
outcomes among the included studies, with in-hospital
or short-term mortality ranging between 8% and 65%, sug-
gest the need for additional randomized studies in this
area to more accurately define the factors associated with
positive and negative outcomes during ECMO for ARDS.
Conclusions
Progress in specific treatments for ARDS beyond lung-
protective strategies of mechanical ventilation and conser-
vative fluid management has not yet been realized. To
develop novel therapies, we need to improve our ability to
define appropriate molecular targets for preclinical devel-
opment and, using relevant animal models and human
models, develop better methods to determine the clinical
value of novel ARDS agents. Clinical trials must have
meaningful endpoints and use the available observational
and meta-analytic data to inform design. Biomarker-
driven studies or defined ARDS subsets should be consid-
ered to categorize specific ‘at risk’ populations most likely
to benefit from a new treatment. These innovations have
been evident in the past year in respiratory critical care re-
search, in laboratory studies, in observational research that
attempts to better define diagnosis and prognosis, in inter-
ventions aimed at defining further benefit that can be
gained from protective lung ventilation strategies, and in
the evaluation of new therapies for the treatment of this
devastating syndrome.Abbreviations
ARDS: Acute respiratory distress syndrome; BAL: Bronchoalveolar lavage;
CO2: Carbon dioxide; CPAP: Continuous positive airway pressure;
CT: Computed tomography; ECMO: Extra-corporeal membrane oxygenation;
EVLW: Extra-vascular lung water; HCA: Hypercapnic acidosis; HFOV: High-
frequency oscillatory ventilation; IL: Interleukin; NIV: Non-invasive ventilation;
OSCILLATE: Oscillation for acute respiratory distress syndrome treated early;
PaCO2: Arterial partial pressure of carbon dioxide; PaO2/FiO2: Arterial partial
Curley and Slutsky Critical Care 2014, 18:577 Page 8 of 10
http://ccforum.com/content/18/5/577pressure of oxygen/fraction of inspired oxygen; PDGF: Platelet-derived
growth factor; PEEP: Positive end-expiratory pressure; Pplat: Inspiratory
plateau pressure; RCT: Randomized controlled trial; sPLA2: Secretory
phospholipase A2; US: Ultrasound; VILI: Ventilator-induced lung injury;
VR: Ventilatory ratio.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Anesthesia, St Michael’s Hospital, and the Keenan Research
Centre for Biomedical Science of St Michael’s Hospital, 30, Bond Street,
Toronto, ON M5B 1 W8, Canada. 2Department of Anesthesia, University of
Toronto, 27, King’s College Circle, Toronto, ON M5S, Canada. 3Department of
Medicine, St Michael’s Hospital, and the Keenan Research Centre for
Biomedical Science, St Michael’s Hospital, 30 Bond Street, Toronto, ON M5B
1 W8, Canada. 4Interdepartmental Division of Critical Care, University of
Toronto, 27, King’s College Circle, Toronto, ON M5S, Canada.
References
1. Tonelli AR, Zein J, Adams J, Ioannidis JP: Effects of interventions on
survival in acute respiratory distress syndrome: an umbrella review of
159 published randomized trials and 29 meta-analyses. Intensive Care
Med 2014, 40:769–787.
2. Ventilation with lower tidal volumes as compared with traditional tidal
volumes for acute lung injury and the acute respiratory distress
syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J
Med 2000, 342:1301–1308.
3. Guérin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E,
Badet M, Mercat A, Baudin O, Clavel M, Chatellier D, Jaber S, Rosselli S,
Mancebo J, Sirodot M, Hilbert G, Bengler C, Richecoeur J, Gainnier M,
Bayle F, Bourdin G, Leray V, Girard R, Baboi L, Ayzac L, PROSEVA Study
Group: Prone positioning in severe acute respiratory distress syndrome.
N Engl J Med 2013, 368:2159–2168.
4. Kavanagh BP: Therapeutic hypercapnia: careful science, better trials.
Am J Respir Crit Care Med 2005, 171:96–97.
5. Marini JJ: Limitations of clinical trials in acute lung injury and acute
respiratory distress syndrome. Curr Opin Crit Care 2006, 12:25–31.
6. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR,
McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, López CM, Honari S,
Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB,
Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein
BH, Miller-Graziano C, Calvano SE, Mason PH, et al: Genomic responses in
mouse models poorly mimic human inflammatory diseases. Proc Natl
Acad Sci U S A 2013, 110:3507–3512.
7. Mak IW, Evaniew N, Ghert M: Lost in translation: animal models and
clinical trials in cancer treatment. Am J Transl Res 2014, 6:114–118.
8. Dirnagl U, Lauritzen M: Fighting publication bias: introducing the
Negative Results section. J Cereb Blood Flow Metab 2010, 30:1263–1264.
9. Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR: Publication
bias in reports of animal stroke studies leads to major overstatement of
efficacy. PLoS Biol 2010, 8:e1000344.
10. Ledford H: Translational research: 4 ways to fix the clinical trial.
Nature 2011, 477:526–528.
11. Setzer F, Oschatz K, Hueter L, Schmidt B, Schwarzkopf K, Schreiber T:
Susceptibility to ventilator induced lung injury is increased in senescent
rats. Crit Care 2013, 17:R99.
12. Gomez CR, Hirano S, Cutro BT, Birjandi S, Baila H, Nomellini V, Kovacs EJ:
Advanced age exacerbates the pulmonary inflammatory response after
lipopolysaccharide exposure. Crit Care Med 2007, 35:246–251.
13. Fleg JL, Strait J: Age-associated changes in cardiovascular structure
and function: a fertile milieu for future disease. Heart Fail Rev 2012,
17:545–554.
14. Rossi AP, Watson NL, Newman AB, Harris TB, Kritchevsky SB, Bauer DC,
Satterfield S, Goodpaster BH, Zamboni M: Effects of body composition and
adipose tissue distribution on respiratory function in elderly men and
women: the health, aging, and body composition study. J Gerontol A Biol
Sci Med Sci 2011, 66:801–808.15. Miller RA: The aging immune system: primer and prospectus. Science
1996, 273:70–74.
16. Ershler WB, Keller ET: Age-associated increased interleukin-6 gene
expression, late-life diseases, and frailty. Annu Rev Med 2000, 51:245–270.
17. Meyer KC: Aging. Proc Am Thorac Soc 2005, 2:433–439.
18. Saito H, Sherwood ER, Varma TK, Evers BM: Effects of aging on mortality,
hypothermia, and cytokine induction in mice with endotoxemia or
sepsis. Mech Ageing Dev 2003, 124:1047–1058.
19. Kim IK, Rhee CK, Yeo CD, Kang HH, Lee DG, Lee SH, Kim JW: Effect of
tyrosine kinase inhibitors, imatinib and nilotinib, in murine
lipopolysaccharide-induced acute lung injury during neutropenia
recovery. Crit Care 2013, 17:R114.
20. Rhee CK, Lee SH, Yoon HK, Kim SC, Lee SY, Kwon SS, Kim YK, Kim KH,
Kim TJ, Kim JW: Effect of nilotinib on bleomycin-induced acute lung
injury and pulmonary fibrosis in mice. Respiration 2011, 82:273–287.
21. Protti A, Andreis DT, Iapichino GE, Monti M, Comini B, Milesi M, Zani L,
Gatti S, Lombardi L, Gattinoni L: High positive end-expiratory pressure:
only a dam against oedema formation? Crit Care 2013, 17:R131.
22. Slutsky AS, Ranieri VM: Ventilator-induced lung injury. N Engl J Med 2013,
369:2126–2136.
23. Dreyfuss D, Soler P, Basset G, Saumon G: High inflation pressure
pulmonary edema. Respective effects of high airway pressure, high tidal
volume, and positive end-expiratory pressure. Am Rev Respir Dis 1988,
137:1159–1164.
24. Muscedere JG, Mullen JB, Gan K, Slutsky AS: Tidal ventilation at low airway
pressures can augment lung injury. Am J Respir Crit Care Med 1994,
149:1327–1334.
25. Egan EA: Response of alveolar epithelial solute permeability to
changes in lung inflation. J Appl Physiol Respir Environ Exerc Physiol 1980,
49:1032–1036.
26. de Prost N, Dreyfuss D, Saumon G: Evaluation of two-way protein fluxes
across the alveolo-capillary membrane by scintigraphy in rats: effect of
lung inflation. J Appl Physiol (1985) 2007, 102:794–802.
27. Ramanathan R, Mason GR, Raj JU: Effect of mechanical ventilation and
barotrauma on pulmonary clearance of 99mtechnetium
diethylenetriamine pentaacetate in lambs. Pediatr Res 1990, 27:70–74.
28. Vecchi V, Langer T, Bellomi M, Rampinelli C, Chung KK, Cancio LC,
Gattinoni L, Batchinsky AI: Low-dose CT for quantitative analysis in acute
respiratory distress syndrome. Crit Care 2013, 17:R183.
29. Chiumello D, Langer T, Vecchi V, Luoni S, Colombo A, Brioni M, Froio S,
Cigada I, Coppola S, Protti A, Lazzerini M, Gattinoni L: Low-dose chest
computed tomography for quantitative and visual anatomical analysis in
patients with acute respiratory distress syndrome. Intensive Care Med
2014, 40:691–699.
30. Tobin MJ: Culmination of an era in research on the acute respiratory
distress syndrome. N Engl J Med 2000, 342:1360–1361.
31. Stewart TE, Meade MO, Cook DJ, Granton JT, Hodder RV, Lapinsky SE,
Mazer CD, McLean RF, Rogovein TS, Schouten BD, Todd TR, Slutsky AS:
Evaluation of a ventilation strategy to prevent barotrauma in patients
at high risk for acute respiratory distress syndrome. Pressure- and
Volume-Limited Ventilation Strategy Group. N Engl J Med 1998,
338:355–361.
32. Curley MA, Hibberd PL, Fineman LD, Wypij D, Shih MC, Thompson JE,
Grant MJ, Barr FE, Cvijanovich NZ, Sorce L, Luckett PM, Matthay MA,
Arnold JH: Effect of prone positioning on clinical outcomes in children
with acute lung injury: a randomized controlled trial. JAMA 2005,
294:229–237.
33. Meade MO, Cook DJ, Guyatt GH, Slutsky AS, Arabi YM, Cooper DJ, Davies
AR, Hand LE, Zhou Q, Thabane L, Austin P, Lapinsky S, Baxter A, Russell J,
Skrobik Y, Ronco JJ, Stewart TE, Lung Open Ventilation Study Investigators:
Ventilation strategy using low tidal volumes, recruitment maneuvers,
and high positive end-expiratory pressure for acute lung injury and
acute respiratory distress syndrome: a randomized controlled trial.
JAMA 2008, 299:637–645.
34. Terragni PP, Rosboch G, Tealdi A, Corno E, Menaldo E, Davini O, Gandini G,
Herrmann P, Mascia L, Quintel M, Slutsky AS, Gattinoni L, Ranieri VM: Tidal
hyperinflation during low tidal volume ventilation in acute respiratory
distress syndrome. Am J Respir Crit Care Med 2007, 175:160–166.
35. Gattinoni L, Caironi P, Pelosi P, Goodman LR: What has computed
tomography taught us about the acute respiratory distress syndrome?
Am J Respir Crit Care Med 2001, 164:1701–1711.
Curley and Slutsky Critical Care 2014, 18:577 Page 9 of 10
http://ccforum.com/content/18/5/57736. Laffey JG, Engelberts D, Kavanagh BP: Injurious effects of hypocapnic
alkalosis in the isolated lung. Am J Respir Crit Care Med 2000,
162:399–405.
37. Gattinoni L, Pesenti A: The concept of ‘baby lung’. Intensive Care Med 2005,
31:776–784.
38. Fanelli V, Mascia L, Puntorieri V, Assenzio B, Elia V, Fornaro G, Martin EL,
Bosco M, Delsedime L, Fiore T, Grasso S, Ranieri VM: Pulmonary atelectasis
during low stretch ventilation: ‘open lung’ versus ‘lung rest’ strategy.
Crit Care Med 2009, 37:1046–1053.
39. Duggan M, Kavanagh BP: Pulmonary atelectasis: a pathogenic
perioperative entity. Anesthesiology 2005, 102:838–854.
40. Retamal J, Libuy J, Jimenez M, Delgado M, Besa C, Bugedo G, Bruhn A:
Preliminary study of ventilation with 4 ml/kg tidal volume in acute
respiratory distress syndrome: feasibility and effects on cyclic
recruitment - derecruitment and hyperinflation. Crit Care 2013, 17:R16.
41. Hotchkiss JR Jr, Blanch L, Murias G, Adams AB, Olson DA, Wangensteen OD,
Leo PH, Marini JJ: Effects of decreased respiratory frequency on
ventilator-induced lung injury. Am J Respir Crit Care Med 2000,
161:463–468.
42. Curley GF, Laffey JG, Kavanagh BP: CrossTalk proposal: there is added
benefit to providing permissive hypercapnia in the treatment of ARDS.
J Physiol 2013, 591:2763–2765.
43. Kregenow DA, Rubenfeld GD, Hudson LD, Swenson ER: Hypercapnic
acidosis and mortality in acute lung injury. Crit Care Med 2006, 34:1–7.
44. Natalini G, Minelli C, Rosano A, Ferretti P, Militano CR, De Feo C, Bernardini
A: Cardiac index and oxygen delivery during low and high tidal volume
ventilation strategies in patients with acute respiratory distress
syndrome: a crossover randomized clinical trial. Crit Care 2013,
17:R146.
45. Stengl M, Ledvinova L, Chvojka J, Benes J, Jarkovska D, Holas J, Soukup P,
Sviglerova J, Matejovic M: Effects of clinically relevant acute hypercapnic
and metabolic acidosis on the cardiovascular system: an experimental
porcine study. Crit Care 2013, 17:R303.
46. Fuller BM, Mohr NM, Drewry AM, Carpenter CR: Lower tidal volume at
initiation of mechanical ventilation may reduce progression to acute
respiratory distress syndrome: a systematic review. Crit Care 2013, 17:R11.
47. Determann RM, Royakkers A, Wolthuis EK, Vlaar AP, Choi G, Paulus F,
Hofstra JJ, de Graaff MJ, Korevaar JC, Schultz MJ: Ventilation with lower
tidal volumes as compared with conventional tidal volumes for patients
without acute lung injury: a preventive randomized controlled trial.
Crit Care 2010, 14:R1.
48. Futier E, Constantin JM, Paugam-Burtz C, Pascal J, Eurin M, Neuschwander A,
Marret E, Beaussier M, Gutton C, Lefrant JY, Allaouchiche B, Verzilli D, Leone M,
De Jong A, Bazin JE, Pereira B, Jaber S, IMPROVE Study Group: A trial of
intraoperative low-tidal-volume ventilation in abdominal surgery. N Engl J
Med 2013, 369:428–437.
49. PROVE Network Investigators for the Clinical Trial Network of the European
Society of Anaesthesiology, Hemmes SN, Gama de Abreu M, Pelosi P,
Schultz MJ: High versus low positive end-expiratory pressure during
general anaesthesia for open abdominal surgery (PROVHILO trial): a
multicentre randomised controlled trial. Lancet 2014, 384:495–503.
50. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS: Non-invasive positive
pressure ventilation to treat respiratory failure resulting from
exacerbations of chronic obstructive pulmonary disease: Cochrane
systematic review and meta-analysis. BMJ 2003, 326:185.
51. Masip J, Roque M, Sanchez B, Fernandez R, Subirana M, Exposito JA:
Noninvasive ventilation in acute cardiogenic pulmonary edema:
systematic review and meta-analysis. JAMA 2005, 294:3124–3130.
52. Antonelli M, Conti G, Esquinas A, Montini L, Maggiore SM, Bello G, Rocco M,
Maviglia R, Pennisi MA, Gonzalez-Diaz G, Meduri GU: A multiple-center
survey on the use in clinical practice of noninvasive ventilation as a
first-line intervention for acute respiratory distress syndrome. Crit Care
Med 2007, 35:18–25.
53. Thille AW, Contou D, Fragnoli C, Cordoba-Izquierdo A, Boissier F,
Brun-Buisson C: Non-invasive ventilation for acute hypoxemic respiratory
failure: intubation rate and risk factors. Crit Care 2013, 17:R269.
54. Ornico SR, Lobo SM, Sanches HS, Deberaldini M, Tofoli LT, Vidal AM,
Schettino GP, Amato MB, Carvalho CR, Barbas CS: Noninvasive ventilation
immediately after extubation improves weaning outcome after acute
respiratory failure: a randomized controlled trial. Crit Care 2013,
17:R39.55. Demoule A, Girou E, Richard JC, Taille S, Brochard L: Benefits and risks of
success or failure of noninvasive ventilation. Intensive Care Med 2006,
32:1756–1765.
56. Burns KE, Adhikari NK, Keenan SP, Meade M: Use of non-invasive
ventilation to wean critically ill adults off invasive ventilation: meta-analysis
and systematic review. BMJ 2009, 338:b1574.
57. Esteban A, Frutos-Vivar F, Ferguson ND, Arabi Y, Apezteguía C, González M,
Epstein SK, Hill NS, Nava S, Soares MA, D'Empaire G, Alía I, Anzueto A:
Noninvasive positive-pressure ventilation for respiratory failure after
extubation. N Engl J Med 2004, 350:2452–2460.
58. Oto J, Li Q, Kimball WR, Wang J, Sabouri AS, Harrell PG, Kacmarek RM,
Jiang Y: Continuous positive airway pressure and ventilation are more
effective with a nasal mask than a full face mask in unconscious
subjects: a randomized controlled trial. Crit Care 2013, 17:R300.
59. Villar J, Pérez-Méndez L, López J, Belda J, Blanco J, Saralegui I, Suárez-Sipmann
F, López J, Lubillo S, Kacmarek RM, HELP Network: An early PEEP/FIO2 trial
identifies different degrees of lung injury in patients with acute respiratory
distress syndrome. Am J Respir Crit Care Med 2007, 176:795–804.
60. Villar J, Pérez-Méndez L, Blanco J, Añón JM, Blanch L, Belda J, Santos-Bouza
A, Fernández RL, Kacmarek RM, Spanish Initiative for Epidemiology,
Stratification, and Therapies for ARDS (SIESTA) Network: A universal definition
of ARDS: the PaO2/FiO2 ratio under a standard ventilatory setting - a
prospective, multicenter validation study. Intensive Care Med 2013,
39:583–592.
61. Hernu R, Wallet F, Thiollière F, Martin O, Richard JC, Schmitt Z, Wallon G,
Delannoy B, Rimmelé T, Démaret C, Magnin C, Vallin H, Lepape A, Baboi L,
Argaud L, Piriou V, Allaouchiche B, Aubrun F, Bastien O, Lehot JJ, Ayzac L,
Guérin C: An attempt to validate the modification of the American-European
consensus definition of acute lung injury/acute respiratory distress syndrome
by the Berlin definition in a university hospital. Intensive Care Med 2013,
39:2161–2170.
62. Caser EB, Zandonade E, Pereira E, Gama AM, Barbas CS: Impact of distinct
definitions of acute lung injury on its incidence and outcomes in Brazilian
ICUs: prospective evaluation of 7,133 patients. Crit Care Med 2014, 42:574–582.
63. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A,
Jaber S, Arnal JM, Perez D, Seghboyan JM, Constantin JM, Courant P,
Lefrant JY, Guérin C, Prat G, Morange S, Roch A, ACURASYS Study Investigators:
Neuromuscular blockers in early acute respiratory distress syndrome. N Engl
J Med 2010, 363:1107–1116.
64. De Luca D, Lopez-Rodriguez E, Minucci A, Vendittelli F, Gentile L, Stival E,
Conti G, Piastra M, Antonelli M, Echaide M, Perez-Gil J, Capoluongo ED:
Clinical and biological role of secretory phospholipase A2 in acute
respiratory distress syndrome infants. Crit Care 2013, 17:R163.
65. de Kretser DM, Bensley JG, Pettila V, Linko R, Hedger MP, Hayward S,
Allan CA, McLachlan RI, Ludlow H, Phillips DJ: Serum activin A and B levels
predict outcome in patients with acute respiratory failure: a prospective
cohort study. Crit Care 2013, 17:R263.
66. Yoo H, Suh GY, Jeong BH, Lim SY, Chung MP, Jung Kwon O, Jeon K:
Etiologies, diagnostic strategies, and outcomes of diffuse pulmonary
infiltrates causing acute respiratory failure in cancer patients: a
retrospective observational study. Crit Care 2013, 17:R150.
67. Azoulay E, Mokart D, Lambert J, Lemiale V, Rabbat A, Kouatchet A,
Vincent F, Gruson D, Bruneel F, Epinette-Branche G, Lafabrie A, Hamidfar-Roy R,
Cracco C, Renard B, Tonnelier JM, Blot F, Chevret S, Schlemmer B: Diagnostic
strategy for hematology and oncology patients with acute respiratory
failure: randomized controlled trial. Am J Respir Crit Care Med 2010,
182:1038–1046.
68. Kirkpatrick AW, Sirois M, Laupland KB, Liu D, Rowan K, Ball CG, Hameed SM,
Brown R, Simons R, Dulchavsky SA, Hamiilton DR, Nicolaou S: Hand-held
thoracic sonography for detecting post-traumatic pneumothoraces: the
Extended Focused Assessment with Sonography for Trauma (EFAST).
J Trauma 2004, 57:288–295.
69. Alrajab S, Youssef AM, Akkus NI, Caldito G: Pleural ultrasonography versus
chest radiography for the diagnosis of pneumothorax: review of the
literature and meta-analysis. Crit Care 2013, 17:R208.
70. Luhr OR, Karlsson M, Thorsteinsson A, Rylander C, Frostell CG: The impact
of respiratory variables on mortality in non-ARDS and ARDS patients
requiring mechanical ventilation. Intensive Care Med 2000, 26:508–517.
71. Nuckton TJ, Alonso JA, Kallet RH, Daniel BM, Pittet JF, Eisner MD, Matthay
MA: Pulmonary dead-space fraction as a risk factor for death in the acute
respiratory distress syndrome. N Engl J Med 2002, 346:1281–1286.
Curley and Slutsky Critical Care 2014, 18:577 Page 10 of 10
http://ccforum.com/content/18/5/57772. Ware LB: Prognostic determinants of acute respiratory distress
syndrome in adults: impact on clinical trial design. Crit Care Med 2005,
33(3 Suppl):S217–S222.
73. Gajic O, Afessa B, Thompson BT, Frutos-Vivar F, Malinchoc M, Rubenfeld GD,
Esteban A, Anzueto A, Hubmayr RD, Second International Study of Mechanical
Ventilation and ARDS-net Investigators: Prediction of death and prolonged
mechanical ventilation in acute lung injury. Crit Care 2007, 11:R53.
74. Supinski GS, Callahan LA: Diaphragm weakness in mechanically ventilated
critically ill patients. Crit Care 2013, 17:R120.
75. Karakurt Z, Fanfulla F, Ceriana P, Carlucci A, Grassi M, Colombo R, Karakurt S,
Nava S: Physiologic determinants of prolonged mechanical ventilation in
patients after major surgery. J Crit Care 2012, 27:221. e229-e216.
76. Watson AC, Hughes PD, Louise Harris M, Hart N, Ware RJ, Wendon J,
Green M, Moxham J: Measurement of twitch transdiaphragmatic,
esophageal, and endotracheal tube pressure with bilateral anterolateral
magnetic phrenic nerve stimulation in patients in the intensive care
unit. Crit Care Med 2001, 29:1325–1331.
77. Daniel Martin A, Smith BK, Gabrielli A: Mechanical ventilation, diaphragm
weakness and weaning: a rehabilitation perspective. Respir Physiol
Neurobiol 2013, 189:377–383.
78. Sinha P, Fauvel NJ, Singh P, Soni N: Analysis of ventilatory ratio as a novel
method to monitor ventilatory adequacy at the bedside. Crit Care 2013,
17:R34.
79. Al-Rawas N, Banner MJ, Euliano NR, Tams CG, Brown J, Martin AD, Gabrielli
A: Expiratory time constant for determinations of plateau pressure,
respiratory system compliance, and total resistance. Crit Care 2013,
17:R23.
80. Carlucci A, Pisani L, Ceriana P, Malovini A, Nava S: Patient-ventilator
asynchronies: may the respiratory mechanics play a role? Crit Care 2013,
17:R54.
81. Kushimoto S, Endo T, Yamanouchi S, Sakamoto T, Ishikura H, Kitazawa Y,
Taira Y, Okuchi K, Tagami T, Watanabe A, Yamaguchi J, Yoshikawa K, Sugita
M, Kase Y, Kanemura T, Takahashi H, Kuroki Y, Izumino H, Rinka H, Seo R,
Takatori M, Kaneko T, Nakamura T, Irahara T, Saito N, PiCCO Pulmonary
Edema Study Group: Relationship between extravascular lung water and
severity categories of acute respiratory distress syndrome by the Berlin
definition. Crit Care 2013, 17:R132.
82. Camporota L, Sherry T, Smith J, Lei K, McLuckie A, Beale R: Physiological
predictors of survival during high-frequency oscillatory ventilation in
adults with acute respiratory distress syndrome. Crit Care 2013,
17:R40.
83. Aubron C, Cheng AC, Pilcher D, Leong T, Magrin G, Cooper DJ, Scheinkestel C,
Pellegrino V: Factors associated with outcomes of patients on
extracorporeal membrane oxygenation support: a 5-year cohort study.
Crit Care 2013, 17:R73.
84. Ferguson ND, Cook DJ, Guyatt GH, Mehta S, Hand L, Austin P, Zhou Q,
Matte A, Walter SD, Lamontagne F, Granton JT, Arabi YM, Arroliga AC,
Stewart TE, Slutsky AS, Meade MO, OSCILLATE Trial Investigators;
Canadian Critical Care Trials Group: High-frequency oscillation in
early acute respiratory distress syndrome. N Engl J Med 2013,
368:795–805.
85. Young D, Lamb SE, Shah S, MacKenzie I, Tunnicliffe W, Lall R,
Rowan K, Cuthbertson BH, Group OS: High-frequency oscillation
for acute respiratory distress syndrome. N Engl J Med 2013,
368:806–813.
86. Hager DN, Krishnan JA, Hayden DL, Brower RG, ARDS Clinical Trials Network:
Tidal volume reduction in patients with acute lung injury when plateau
pressures are not high. Am J Respir Crit Care Med 2005, 172:1241–1245.
87. Terragni PP, Del Sorbo L, Mascia L, Urbino R, Martin EL, Birocco A, Faggiano
C, Quintel M, Gattinoni L, Ranieri VM: Tidal volume lower than 6 ml/kg
enhances lung protection: role of extracorporeal carbon dioxide
removal. Anesthesiology 2009, 111:826–835.
88. Forster C, Schriewer J, John S, Eckardt KU, Willam C: Low-flow CO2 removal
integrated into a renal-replacement circuit can reduce acidosis and
decrease vasopressor requirements. Crit Care 2013, 17:R154.
89. Spieth PM, Güldner A, Huhle R, Beda A, Bluth T, Schreiter D, Ragaller M,
Gottschlich B, Kiss T, Jaber S, Pelosi P, Koch T, Gama de Abreu M:
Short-term effects of noisy pressure support ventilation in patients with
acute hypoxemic respiratory failure. Crit Care 2013, 17:R261.90. Piquilloud L, Vignaux L, Bialais E, Roeseler J, Sottiaux T, Laterre PF,
Jolliet P, Tassaux D: Neurally adjusted ventilatory assist improves
patient-ventilator interaction. Intensive Care Med 2011, 37:263–271.
91. Costa R, Spinazzola G, Cipriani F, Ferrone G, Festa O, Arcangeli A, Antonelli
M, Proietti R, Conti G: A physiologic comparison of proportional assist
ventilation with load-adjustable gain factors (PAV+) versus pressure
support ventilation (PSV). Intensive Care Med 2011, 37:1494–1500.
92. Alhazzani W, Alshahrani M, Jaeschke R, Forel JM, Papazian L, Sevransky J,
Meade MO: Neuromuscular blocking agents in acute respiratory distress
syndrome: a systematic review and meta-analysis of randomized
controlled trials. Crit Care 2013, 17:R43.
93. Zangrillo A, Biondi-Zoccai G, Landoni G, Frati G, Patroniti N, Pesenti A,
Pappalardo F: Extracorporeal membrane oxygenation (ECMO) in patients
with H1N1 influenza infection: a systematic review and meta-analysis
including 8 studies and 266 patients receiving ECMO. Crit Care 2013,
17:R30.
doi:10.1186/s13054-014-0577-y
Cite this article as: Curley and Slutsky: Year in review 2013: Critical Care -
respirology. Critical Care 2014 18:577.
